Neuropace Stock Today
| NPCE Stock | USD 12.23 0.78 6.00% |
PerformanceWeak
| Odds Of DistressVery High
|
Neuropace is trading at 12.23 as of the 5th of April 2025, a 6 percent decrease since the beginning of the trading day. The stock's lowest day price was 11.83. Neuropace has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 5th of January 2025 and ending today, the 5th of April 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 22nd of April 2021 | Category Healthcare | Classification Health Care |
NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 32.56 M outstanding shares of which 308.34 K shares are now shorted by private and institutional investors with about 0.87 trading days to cover. More on Neuropace
Moving together with Neuropace Stock
Moving against Neuropace Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Neuropace Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Joel Becker | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Medical Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Medical Equipment, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNeuropace can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neuropace's financial leverage. It provides some insight into what part of Neuropace's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuropace (NPCE) is traded on NASDAQ Exchange in USA. It is located in 455 North Bernardo Avenue, Mountain View, CA, United States, 94043 and employs 184 people. Neuropace is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 398.21 M. Neuropace conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 32.56 M outstanding shares of which 308.34 K shares are now shorted by private and institutional investors with about 0.87 trading days to cover.
Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Check Neuropace Probability Of Bankruptcy
Ownership AllocationNeuropace maintains a total of 32.56 Million outstanding shares. Over half of Neuropace's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Neuropace Ownership Details
Neuropace Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 323 K | |
| Fmr Inc | 2024-12-31 | 249.7 K | |
| Northern Trust Corp | 2024-12-31 | 184.8 K | |
| State Street Corp | 2024-12-31 | 148.3 K | |
| Jane Street Group Llc | 2024-12-31 | 100.1 K | |
| Renaissance Technologies Corp | 2024-12-31 | 86.3 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 64.8 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 57.1 K | |
| Gsa Capital Partners Llp | 2024-12-31 | 56.4 K | |
| Kck Ltd | 2024-12-31 | 5.3 M | |
| Orbimed Advisors, Llc | 2024-12-31 | 3.4 M |
Neuropace Historical Income Statement
Neuropace Stock Against Markets
Neuropace Corporate Management
| Irina Ridley | Chief Secretary | Profile | |
| Chi Nguyen | VP Marketing | Profile | |
| Kelley Nicholas | Vice Sales | Profile | |
| Michael Favet | CEO Pres | Profile | |
| Katie Keller | Vice Marketing | Profile | |
| Martha MD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 0.192 | Return On Assets | Return On Equity |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.